Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$55.14 USD
-3.62 (-6.16%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $55.08 -0.06 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Nektar Therapeutics has a market cap of $1.12B, which represents its share price of $58.76 multiplied by its outstanding shares number of 19.02M. As a small-cap company, NKTR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NKTR 55.14 -3.62(-6.16%)
Will NKTR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
Other News for NKTR
NKTR forms Bearish Engulfing on September 20
NKTR makes New 52 Week Closing High on September 19
Analysts Are Bullish on These Healthcare Stocks: Edwards Lifesciences (EW), Nektar Therapeutics (NKTR)
Oppenheimer Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Embecta Corporation (EMBC) and Replimune Group (REPL)